Triglycerides Mediate the Influence of Body Mass Index on Non-Alcoholic Fatty Liver Disease in a Non-Obese Chinese Population with Normal Low-Density Lipoprotein Cholesterol Levels

Overview

Journal Obes Facts

Publisher Karger

Specialty Endocrinology

Date 2024 Jan 24

PMID 38266508

Authors

Xixi Han

Jingwen Kong

Hemin Zhang

Yuan Zhao

Yafeng Zheng

Chao Wei

Affiliations

Soon will be listed here.

Abstract

Introduction: Over 25% of the world's population has non-obese or lean non-alcoholic fatty liver disease (NAFLD), and the prevalence is higher than average in Asia. The present study focused on the relationship between body mass index (BMI) and non-obese NAFLD in non-overweight people in China, particularly the influence of triglycerides (TG) in the pathogenesis of non-obese NAFLD. The findings suggest new treatments for NAFLD patients with normal BMI, as well as provide an early warning system for the understanding and prevention of NAFLD in non-obese patients.

Methods: This cross-sectional study enrolled 159,959 Chinese subjects with BMI <24 kg/m2 and normal levels of low-density lipoprotein cholesterol (LDL-c). The average age was 40.21 ± 13.88 years, and males accounted for 45.7%. A total of 15,907 (9.94%) patients with NAFLD were diagnosed by ultrasonography. Biochemical indicators were measured using an automated analyzer (Abbott AxSYM). The BMI (kg/m2) was calculated from the weight (kg)/height in square meters (m2). The BMI quartile was used as the column-stratified variable to determine the baseline distribution, and logistic regression analysis was used to assess the relationship between NAFLD and its risk factors, with multiple logistic regression used to assess the relationships between BMI or TG and NAFLD and multivariate linear regression used to analyze the association between BMI and TG, while mediation analysis was used to assess the mediation effect of TG.

Results: After adjustment of all covariates, the odds ratios were 1.788 (95% CI: 1.749-1.829; p < 0.00001) and 1.491 (95% CI: 1.451-1.532; p < 0.00001) for the association between BMI and TG with NAFLD incidence. The multivariate linear regression coefficient of BMI and TG was β = 0.027 (95% CI: 0.023-0.030; p < 0.00001). Mediation analysis showed that BMI contributed to 10.81% of lean NAFLD with a mediation effect of 2.98%.

Conclusion: In a Chinese population with BMI <24 kg/m2 and normal LDL-c levels, BMI and TG were found to be independent predictors of NAFLD. The direct effect of BMI on non-obese NAFLD was 10.41%. The TG level was found to partially mediate the association.

References

Wang Q, You H, Ou X, Zhao X, Sun Y, Wang M . Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis. Hepatol Int. 2019; 13(6):766-776. DOI: 10.1007/s12072-019-09982-z. View

Sun D, Wu S, Liu W, Wang L, Chen Y, Zhang D . Association of low-density lipoprotein cholesterol within the normal range and NAFLD in the non-obese Chinese population: a cross-sectional and longitudinal study. BMJ Open. 2016; 6(12):e013781. PMC: 5168665. DOI: 10.1136/bmjopen-2016-013781. View

Fan J, Kim S, Wong V . New trends on obesity and NAFLD in Asia. J Hepatol. 2017; 67(4):862-873. DOI: 10.1016/j.jhep.2017.06.003. View

Wong V, Wong G, Chan R, Shu S, Cheung B, Li L . Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018; 69(6):1349-1356. DOI: 10.1016/j.jhep.2018.08.011. View

Li Y, Chen Y, Tian X, Zhang S, Jiao J . Comparison of Clinical Characteristics Between Obese and Non-Obese Patients with Nonalcoholic Fatty Liver Disease (NAFLD). Diabetes Metab Syndr Obes. 2021; 14:2029-2039. PMC: 8110261. DOI: 10.2147/DMSO.S304634. View

Simons P, Valkenburg O, van de Waarenburg M, van Greevenbroek M, Kooi M, Jansen J . Serum sex hormone-binding globulin is a mediator of the association between intrahepatic lipid content and type 2 diabetes: the Maastricht Study. Diabetologia. 2022; 66(1):213-222. PMC: 9729158. DOI: 10.1007/s00125-022-05790-7. View

Cigrovski Berkovic M, Bilic-Curcic I, Mrzljak A, Cigrovski V . NAFLD and Physical Exercise: Ready, Steady, Go!. Front Nutr. 2021; 8:734859. PMC: 8523679. DOI: 10.3389/fnut.2021.734859. View

Zhang X, Wang T, Targher G, Byrne C, Zheng M . Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease. Diabetes Metab J. 2022; 46(3):391-401. PMC: 9171159. DOI: 10.4093/dmj.2022.0048. View

Xing J, Guan X, Zhang Q, Chen S, Wu S, Sun X . Triglycerides Mediate Body Mass Index and Nonalcoholic Fatty Liver Disease: A Population-Based Study. Obes Facts. 2021; 14(2):190-196. PMC: 8138251. DOI: 10.1159/000514848. View

10.

Dai H, Xiang J, Hou Y, Xuan L, Wang T, Li M . Fat mass to fat-free mass ratio and the risk of non-alcoholic fatty liver disease and fibrosis in non-obese and obese individuals. Nutr Metab (Lond). 2021; 18(1):21. PMC: 7893940. DOI: 10.1186/s12986-021-00551-6. View

11.

Peng Y, Zeng Q, Wan L, Ma E, Li H, Yang X . GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity. Nat Commun. 2021; 12(1):7004. PMC: 8636488. DOI: 10.1038/s41467-021-27309-1. View

12.

Zhou J, Zhou F, Wang W, Zhang X, Ji Y, Zhang P . Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020; 71(5):1851-1864. DOI: 10.1002/hep.31150. View

13.

Chan W . Comparison between obese and non-obese nonalcoholic fatty liver disease. Clin Mol Hepatol. 2022; 29(Suppl):S58-S67. PMC: 10029940. DOI: 10.3350/cmh.2022.0350. View

14.

Shi Y, Wang Q, Sun Y, Zhao X, Kong Y, Ou X . The Prevalence of Lean/Nonobese Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2019; 54(4):378-387. DOI: 10.1097/MCG.0000000000001270. View

15.

Yip T, Lee H, Chan W, Wong G, Wong V . Asian perspective on NAFLD-associated HCC. J Hepatol. 2021; 76(3):726-734. DOI: 10.1016/j.jhep.2021.09.024. View

16.

Yabe Y, Chihara K, Oshida N, Kamimaki T, Hasegawa N, Isobe T . Survey of Dietary Habits and Physical Activity in Japanese Patients with Non-Obese Non-Alcoholic Fatty Liver Disease. Nutrients. 2023; 15(12). PMC: 10304426. DOI: 10.3390/nu15122764. View

17.

Zhang Z, Xun Y, Rong S, Yan L, Sorelle J, Li X . Loss of immunity-related GTPase GM4951 leads to nonalcoholic fatty liver disease without obesity. Nat Commun. 2022; 13(1):4136. PMC: 9288484. DOI: 10.1038/s41467-022-31812-4. View

18.

Zeng M, Fan J, Lu L, Li Y, Chen C, Wang B . Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis. 2008; 9(2):108-12. DOI: 10.1111/j.1751-2980.2008.00331.x. View

19.

Ahadi M, Molooghi K, Masoudifar N, Namdar A, Vossoughinia H, Farzanehfar M . A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol. 2020; 36(6):1497-1507. DOI: 10.1111/jgh.15353. View

20.

Videla L, Valenzuela R . Perspectives in liver redox imbalance: Toxicological and pharmacological aspects underlying iron overloading, nonalcoholic fatty liver disease, and thyroid hormone action. Biofactors. 2021; 48(2):400-415. DOI: 10.1002/biof.1797. View